Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.
about
Chronic inflammation and the role for cofactors (hepatitis C, drug abuse, antiretroviral drug toxicity, aging) in HAND persistenceAbility of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent forSignificance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.The significance of low-level viraemia in diverse settings: analysis of the Treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assayResidual viremia is preceding viral blips and persistent low-level viremia in treated HIV-1 patients.HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failureCobas ampliprep/cobas TaqMan HIV-1 v2.0 assay: consequences at the cohort level.HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV/hepatitis C virus-coinfected patients.Neuropathogenesis of HIV-associated neurocognitive disorders: roles for immune activation, HIV blipping and viral tropismThe significance of HIV 'blips' in resource-limited settings: is it the same? analysis of the treat Asia HIV Observational Database (TAHOD) and the Australian HIV Observational Database (AHOD).Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.Viral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in GhanaViral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levelsInduction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral TherapyHIV Infection Is Associated With Progression of Subclinical Carotid Atherosclerosis.Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical TrialCD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapyFrequent Episodes of Detectable Viremia in HIV Treatment-Experienced Children is Associated with a Decline in CD4+ T-cells Over Time.Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care.Study design issues in evaluating immune biomarkers.Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment serviceShort communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.Serious Non-AIDS events: Immunopathogenesis and interventional strategies.Is forced migration a barrier to treatment success? Similar HIV treatment outcomes among refugees and a surrounding host community in Kuala Lumpur, MalaysiaVirological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.Modelling the evolution of HIV-1 virulence in response to imperfect therapy and prophylaxisPoor retention in care one-year after viral suppression: a significant predictor of viral rebound.Estimation and assessment of markov multistate models with intermittent observations on individuals.Liver stiffness is not associated with short- and long-term plasma HIV RNA replication in immunocompetent patients with HIV infection and with HIV/HCV coinfection.HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa.Evaluation of the Aptima(®) HIV-1 Quant Dx assay for HIV-1 RNA viral load detection and quantitation in plasma of HIV-1-infected individuals: A comparison with Abbott RealTime HIV-1 assay.TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.Estimation of state occupancy probabilities in multistate models with dependent intermittent observation, with application to HIV viral rebounds.Increased inflammation in sanctuary sites may explain viral blips in HIV infection.Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART?Backward bifurcations, turning points and rich dynamics in simple disease models.Soluble biomarkers of immune activation and inflammation in HIV infection: impact of 2 years of effective first-line combination antiretroviral therapy.HCV RNA viral load is independent from CD4 cell count and plasma HIV RNA viral load in immunocompetent HIV-HCV co-infected patients: a 3-years follow-up study.
P2860
Q26825762-12A64C49-F3BB-4F8C-AEB6-584AF236A47CQ33703537-BC12418B-2B79-4DDD-A3DE-212C32982E02Q33798584-383179BA-EBF4-431E-9886-9453270FD688Q33934935-0517CFC7-FECF-4C6A-B9B1-279B02E2AB18Q34399511-15FDD43F-21E5-4BE0-ADFC-5EF12D9A2C3DQ34420782-E3967BFE-6F85-4AE3-B4E3-451C3C5DF1EBQ34781706-06F4F380-6713-47BC-923C-C599EA98C61EQ34983777-4F7F0C96-28EE-4B94-A81B-A637194AD4C6Q35033499-8B5866B6-D32E-4CBC-A54D-BE16C0946803Q35057044-1C4E8958-6941-4280-B9FF-5915680E463EQ35091354-8BC8DA4E-A842-4025-ACA8-F281CE858CD3Q35782774-D7E5372E-83B5-4120-9BE3-6887435AD6DBQ35914071-C5BFE031-25E2-4BEF-9CAB-293FB95DCC6EQ36058328-6EF7D8F4-B312-484B-A3C7-0A6EFEF470A1Q36086223-158CA0E4-3AAF-4CC9-A42E-B5DFD29764EAQ36167498-3FFE36A7-10DD-44F9-8158-D46D144E2013Q36306986-E65705C3-4B4B-410F-83F7-931914D87E96Q36784163-7BB964FC-362E-4F15-AA30-E5DD1776E767Q37057964-B41E1CC5-5DFD-4F59-8BB6-9403A2450667Q37135519-A383DDB9-FC50-455C-A432-AC0A85BBDCD1Q37184783-5CB7C219-AAEB-4D63-857B-B70D28E07C22Q37284765-1C5F335A-E693-4578-A078-0D73FEF34E45Q37359256-3DEA0678-AED8-48B5-91A6-1BAEECA2166AQ37418140-1EB77364-5897-4157-868C-9142D9AE934BQ37526208-D53995A5-6683-46AC-B91A-0C1D8ADABDA8Q37582477-E3F99099-837B-4C8E-A382-A3FA4D28E6B8Q37661125-1FF62083-C9C2-42D9-A7BA-CA9BC40F099EQ38213484-467C3F76-9B11-49D3-93D3-3AF508C486EEQ38261620-03392F04-07CF-472C-8242-ED02E14745B9Q38606313-87AB6D95-C1A9-4639-94E4-D856B5C1EB89Q39648148-CB1AE5F6-1917-4EC0-B517-0FDB75FF1E90Q40007100-D3C44BF2-9C93-4C0A-9EEB-0B8D03CC50DCQ40280160-E1EE8031-7F1C-468C-9F5F-458072E50263Q40401616-3E7E81FC-6187-4075-A3D0-F2FCE0C6141CQ40451968-C90B1580-A921-4B17-AAE4-B0340D01BD0FQ40604582-A95110B0-1ECB-4F84-810E-7864BBD6B0CDQ40857953-1844D36C-C494-4E8B-9023-16E17F78A9CEQ40884284-9AD919CE-0DE0-41F5-AD3C-3A08B418CA66Q41257300-70D1640E-4B98-40CC-B968-0641C5B768DCQ41984358-66D98431-64F4-4815-8F41-A32BF5887699
P2860
Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Magnitude of virologic blips i ...... : a recurrent events analysis.
@ast
Magnitude of virologic blips i ...... : a recurrent events analysis.
@en
type
label
Magnitude of virologic blips i ...... : a recurrent events analysis.
@ast
Magnitude of virologic blips i ...... : a recurrent events analysis.
@en
prefLabel
Magnitude of virologic blips i ...... : a recurrent events analysis.
@ast
Magnitude of virologic blips i ...... : a recurrent events analysis.
@en
P2093
P2860
P356
P1476
Magnitude of virologic blips i ...... : a recurrent events analysis.
@en
P2093
CANOC Collaboration
Christos Tsoukas
Curtis Cooper
DeSheng Su
J Troy Grennan
Janet Raboud
Marina Klein
Mona R Loutfy
Nima Machouf
P2860
P304
P356
10.1093/INFDIS/JIS104
P407
P577
2012-04-01T00:00:00Z